Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tesaro Inc.

This article was originally published in Start Up

Executive Summary

Just over a year old at the start of June 2011, Tesaro Inc. raised a Series B financing of $101 million. This largest biotech venture financing of the year has enabled the company to start building its oncology pipeline, starting with the December 2010 in-licensing of rolapitant, a Phase III-ready drug candidate for chemotherapy-induced nausea and vomiting.
Advertisement

Related Content

Upheaval And Opportunity Reshape The Oncology Market
Tocagen Inc.
VentiRx Pharmaceuticals Inc.
Start-Up Previews
Polaris Group
Cyterix Pharmaceuticals Inc.
Tragara Pharmaceuticals Inc.
Upheaval And Opportunity Reshape The Oncology Market
Start-Up Previews

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel